

Roberto Salvioni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1235959/publications.pdf>

Version: 2024-02-01

115
papers

5,056
citations

109137

35
h-index

95083

68
g-index

121
all docs

121
docs citations

121
times ranked

4342
citing authors

#	ARTICLE	IF	CITATIONS
1	Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. <i>European Urology Oncology</i> , 2021, 4, 802-810.	2.6	22
2	Radiotherapy after testis-sparing surgery for seminoma in monorchid patients: safety and efficacy. <i>Tumori</i> , 2021, , 030089162199242.	0.6	2
3	The role of individual characteristics in predicting decisional conflict for patients with prostate cancer (PCa): preliminary results. <i>Current Psychology</i> , 2020, 39, 354-363.	1.7	0
4	Identifying an optimal lymph node yield for penile squamous cell carcinoma: prognostic impact of surgical dissection. <i>BJU International</i> , 2020, 125, 82-88.	1.3	20
5	A risk calculator predicting recurrence in lymph node metastatic penile cancer. <i>BJU International</i> , 2020, 126, 577-585.	1.3	12
6	Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 531.e7-531.e15.	0.8	27
7	First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. <i>BJU International</i> , 2018, 121, 348-356.	1.3	70
8	Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 8.e1-8.e8.	0.8	8
9	Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center. <i>Journal of Urology</i> , 2018, 199, 741-747.	0.2	21
10	Italian cultural adaptation of the Memorial Anxiety for Prostate Cancer scale for the population of men on active surveillance. <i>Tumori</i> , 2018, 104, 172-178.	0.6	5
11	Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 60-65.	0.6	4
12	Treatment of Carcinoma In Situ of the Glans Penis With Topical Imiquimod Followed by Carbon Dioxide Laser Excision. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e483-e487.	0.9	7
13	Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. <i>Annals of Oncology</i> , 2017, 28, 1346-1351.	0.6	34
14	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 548-555.e3.	0.9	37
15	Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 213-220.e5.	0.9	27
16	A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 306-312.e3.	0.9	25
17	Eleven-year Management of Prostate Cancer Patients on Active Surveillance: What have We Learned?. <i>Tumori</i> , 2017, 103, 464-474.	0.6	20
18	Multidisciplinary Approach of Prostate Cancer Patients. , 2017, , 281-293.		0

#	ARTICLE	IF	CITATIONS
19	Immunotherapy advances in uro-genital malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 52-64.	2.0	19
20	Interim 18F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future Directions. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 249-254.	0.9	12
21	Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 261-264.e4.	0.9	22
22	Prognostic Factors of Adjuvant Taxane, Cisplatin, and 5-Fluorouracil Chemotherapy for Patients With Penile Squamous Cell Carcinoma After Regional Lymphadenectomy. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 518-523.	0.9	28
23	Tumors of the Penis and Scrotum. , 2016, , 229-273.		0
24	Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients. <i>Journal of Endourology</i> , 2016, 30, 1112-1119.	1.1	20
25	Lifestyle interventions to improve the quality of life of men with prostate cancer: A systematic review of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 13-22.	2.0	30
26	â€œWhat ifâ€¦â€ Decisional Regret in Patients who Discontinued Active Surveillance. <i>Tumori</i> , 2016, 102, 562-568.	0.6	6
27	Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. <i>Journal of Urology</i> , 2016, 196, 95-100.	0.2	70
28	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. <i>Investigational New Drugs</i> , 2016, 34, 236-242.	1.2	21
29	A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 323-330.	0.9	59
30	Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 231-236.	0.9	38
31	The Changing Landscape of Intermediate- and Poor-Risk Germ Cell Tumors: Do We Need to Reclassify Patients With Metastatic Germ Cell Tumors?. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 1-4.	0.9	6
32	Quality of Life and Pain Control following Laparoscopic Retroperitoneal Lymph Node Dissection in Early-stage Nonseminoma. <i>Tumori</i> , 2015, 101, 650-656.	0.6	6
33	Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 479-482.	0.6	26
34	Relationship between lymph node ratio and cancer-specific survival in a contemporary series of patients with penile cancer and lymph node metastases. <i>BJU International</i> , 2015, 116, 727-733.	1.3	23
35	Postchemotherapy Lymphadenectomy in Patients With Metastatic Urothelial Carcinoma: Long-Term Efficacy and Implications for Trial Design. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 80-86.e1.	0.9	17
36	Clinical Outcome in Testicular Sex Cord Stromal Tumors: Testis Sparing vs Radical Orchiectomy and Management of Advanced Disease. <i>Urology</i> , 2015, 85, 402-406.	0.5	47

#	ARTICLE	IF	CITATIONS
37	Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 332.e19-332.e24.	0.8	12
38	Time from Nephrectomy as a Prognostic Factor in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapies: Overall Results from a Large Cohort of Patients. <i>Oncology</i> , 2015, 88, 133-138.	0.9	4
39	Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 385-391.e1.	0.9	4
40	Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. <i>Annals of Oncology</i> , 2015, 26, 657-668.	0.6	71
41	Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 171-177.e1.	0.9	9
42	High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. <i>Annals of Oncology</i> , 2015, 26, 167-172.	0.6	17
43	A Prognostic Model Including Pre- and Postsurgical Variables to Enhance Risk Stratification of Primary Mediastinal Nonseminomatous Germ Cell Tumors: The 27-Year Experience of a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 87-93.e1.	0.9	27
44	Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. <i>British Journal of Cancer</i> , 2014, 110, 26-33.	2.9	16
45	Long-Term Efficacy and Safety Outcomes of Modified (Simplified) MVAC (Methotrexate/Vinblastine/Doxorubicin/Cisplatin) as Frontline Therapy for Unresectable or Metastatic Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 203-209.e1.	0.9	15
46	Predictors of CD34+ Cell Mobilization and Collection in Adult Men With Germ Cell Tumors: Implications for the Salvage Treatment Strategy. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 196-202.e1.	0.9	3
47	PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β 2 (TGF β 2) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. <i>Investigational New Drugs</i> , 2014, 32, 555-560.	1.2	50
48	Interim Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Therapeutic Response to Chemotherapy for Metastatic Transitional Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 433-439.	0.9	24
49	Combination of Paclitaxel, Cisplatin, and Gemcitabine (TPG) for Multiple Relapses or Platinum-Resistant Germ Cell Tumors: Long-Term Outcomes. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 63-69.e1.	0.9	27
50	The Relationship between Characteristics of Inguinal Lymph Nodes and Pelvic Lymph Node Involvement in Penile Squamous Cell Carcinoma: A Single Institution Experience. <i>Journal of Urology</i> , 2014, 191, 977-982.	0.2	75
51	Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 376-376.	0.8	5
52	Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes. <i>Annals of Oncology</i> , 2013, 24, 2887-2892.	0.6	14
53	Persistent CD30 Expression by Embryonal Carcinoma in the Treatment Time Course: Prognostic Significance of a Worthwhile Target for Personalized Treatment. <i>Journal of Urology</i> , 2013, 190, 1919-1924.	0.2	36
54	Predictors of Health-related Quality of Life and Adjustment to Prostate Cancer During Active Surveillance. <i>European Urology</i> , 2013, 64, 30-36.	0.9	81

#	ARTICLE	IF	CITATIONS
55	Prostatic metastases from testicular nonseminomatous germ cell cancer: two case reports and a review of the literature. <i>Tumori</i> , 2013, 99, e203-7.	0.6	1
56	Adherence to Guidelines among Italian Urologists on Imaging Preoperative Staging of Low-Risk Prostate Cancer: Results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy) Trial. <i>Urology</i> , 2013, 81, 100-106.	0.6	10
57	Experience with sorafenib in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2012, 4, 303-313.	0.9	17
58	New Directions for Biologic Targets in Urothelial Carcinoma – Letter. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2306-2306.	1.9	0
59	Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. <i>Lancet Oncology</i> , 2012, 13, 810-816.	5.1	130
60	CT-guided percutaneous cryoablation of renal masses in selected patients. <i>Radiologia Medica</i> , 2012, 117, 593-605.	4.7	7
61	The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. <i>BJU International</i> , 2012, 110, 998-1003.	1.3	47
62	973 LAPAROSCOPIC RETROPERITONEAL LYMPH-NODE DISSECTION (L-RPLND): EVOLUTION TOWARDS A SINGLE-STRATEGY MANAGEMENT IN CLINICAL STAGE I (CS I) NON-SEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS (NSGCT). <i>Journal of Urology</i> , 2011, 185, .	0.2	1
63	Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 284-290.	0.8	10
64	Concordance and Prediction Ability of Original and Reviewed Vascular Invasion and Other Prognostic Parameters of Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors After Retroperitoneal Lymph Node Dissection. <i>Journal of Urology</i> , 2011, 186, 1298-1302.	0.2	21
65	Expectations of survivors, caregivers and healthcare providers for testicular cancer survivorship and quality of life. <i>Tumori</i> , 2011, 97, 367-373.	0.6	14
66	Towards the definition of the best management and prognostic factors of teratoma with malignant transformation: a single-institution case series and new proposal. <i>BJU International</i> , 2011, 107, 1088-1094.	1.3	54
67	Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. <i>BJU International</i> , 2011, 108, 223-227.	1.3	10
68	Teratoma With Somatic-Type Malignant Components in Germ Cell Tumors of the Testis: A Clinicopathologic Analysis of 40 Cases With Outcome Correlation. <i>International Journal of Surgical Pathology</i> , 2011, 19, 321-327.	0.4	66
69	Proof of Activity of Anti-Epidermal Growth Factor Receptor-Targeted Therapy for Relapsed Squamous Cell Carcinoma of the Penis. <i>Journal of Clinical Oncology</i> , 2011, 29, e650-e652.	0.8	74
70	Expectations of survivors, caregivers and healthcare providers for testicular cancer survivorship and quality of life. <i>Tumori</i> , 2011, 97, 367-73.	0.6	11
71	Re: Roisin M. Connolly, John A. McCaffrey. High-Dose Chemotherapy plus Stem Cell Transplantation in Advanced Germ Cell Cancer: A Review. <i>Eur Urol</i> 2009;56:57-64. <i>European Urology</i> , 2010, 57, e5-e6.	0.9	1
72	Retroperitoneal Lymph Node Dissection with No Adjuvant Chemotherapy in Clinical Stage I Nonseminomatous Germ Cell Tumours: Long-Term Outcome and Analysis of Risk Factors of Recurrence. <i>European Urology</i> , 2010, 58, 912-918.	0.9	47

#	ARTICLE	IF	CITATIONS
73	miR-21: an oncomir on strike in prostate cancer. <i>Molecular Cancer</i> , 2010, 9, 12.	7.9	189
74	miR-205 Exerts Tumor-Suppressive Functions in Human Prostate through Down-regulation of Protein Kinase C μ . <i>Cancer Research</i> , 2009, 69, 2287-2295.	0.4	334
75	Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. <i>BJU International</i> , 2009, 104, 340-346.	1.3	34
76	Understanding the somatic-type malignant differentiation in male germ-cell cancer: A work in progress. Response to the article by Spiess et al., Malignant transformation of testicular teratoma: A chemoresistant phenotype. <i>Urol Oncol</i> 2008;26:595-9. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 218.	0.8	0
77	Penile cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 677-685.	0.8	20
78	Case report: renal cell carcinoma presenting as hypertension in pregnancy. <i>Archives of Gynecology and Obstetrics</i> , 2008, 277, 263-265.	0.8	8
79	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. <i>European Urology</i> , 2008, 53, 478-496.	0.9	488
80	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. <i>European Urology</i> , 2008, 53, 497-513.	0.9	243
81	Penoscopically Controlled CO2 Laser Excision for Conservative Treatment of In Situ and T1 Penile Carcinoma: Report on 224 Patients. <i>European Urology</i> , 2008, 54, 875-884.	0.9	115
82	Does oxaliplatin and paclitaxel combination show an activity of some extent in pretreated patients with germ-cell tumors?. <i>Annals of Oncology</i> , 2008, 19, 1509.	0.6	5
83	Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. <i>Annals of Oncology</i> , 2008, 19, 259-264.	0.6	86
84	IGG* Practice Guidelines on Germ Cell Tumor in Adult Male Patients. <i>Tumori</i> , 2008, 94, 96-109.	0.6	12
85	Conservative Surgical Therapy for Leydig Cell Tumor. <i>Journal of Urology</i> , 2007, 178, 507-511.	0.2	69
86	Re: Peter Albers. Management of Stage I Testis Cancer. <i>Eur Urol</i> 2007;51:34-44. <i>European Urology</i> , 2007, 52, 295-296.	0.9	1
87	Vaccination therapy in prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 429-445.	2.0	21
88	Long-Term Followup and Clinical Characteristics of Testicular Leydig Cell Tumor: Experience With 24 Cases. <i>Journal of Urology</i> , 2006, 176, 2040-2043.	0.2	47
89	In regard to Kagan: "The multidisciplinary clinic" (<i>Int J Radiat Oncol Biol Phys</i> 2005;61:967-968). <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 309-310.	0.4	13
90	A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. <i>Annals of Oncology</i> , 2005, 16, 1152-1159.	0.6	246

#	ARTICLE	IF	CITATIONS
91	Treatment Options in Hormone-refractory Metastatic Prostate Carcinoma. <i>Tumori</i> , 2004, 90, 535-546.	0.6	34
92	A Simple Model for Predicting Nodal Metastasis in Patients With Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors Undergoing Retroperitoneal Lymph Node Dissection Only. <i>Journal of Urology</i> , 2004, 171, 172-176.	0.2	69
93	Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis in Childhood and Adolescence: An Analysis of 31 Cases. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 454-458.	0.3	14
94	Salvage high-dose chemotherapy in patients with germ cell tumors. <i>Cancer</i> , 2002, 95, 309-315.	2.0	27
95	Viable Malignant Cells After Primary Chemotherapy for Disseminated Nonseminomatous Germ Cell Tumors: Prognostic Factors and Role of Postsurgery Chemotherapy—Results From an International Study Group. <i>Journal of Clinical Oncology</i> , 2001, 19, 2647-2657.	0.8	264
96	The Role of Adjuvant Treatment in Low-Stage Germ Cell Testicular Tumors. <i>European Urology</i> , 1995, 28, 267-272.	0.9	5
97	Evolution and controversies in the management of low-stage nonseminomatous germ-cell tumors of the testis. <i>World Journal of Urology</i> , 1994, 12, 113-9.	1.2	17
98	Surgery in Non-Seminomatous Germ Cell Tumours of the Testis. , 1994, , 311-317.		1
99	Dexamethasone plus Ondansetron versus Dexamethasone plus Alizapride in the Prevention of Emesis Induced by Cisplatin-Containing Chemotherapies for Urological Cancers. <i>European Urology</i> , 1993, 23, 450-456.	0.9	17
100	An Italian Experience of High-Dose Chemotherapy and Autologous Bone Marrow Transplantation (ABMT) in Germ Cell Tumours. Suggestions for Future Direction. <i>Leukemia and Lymphoma</i> , 1992, 7, 59-63.	0.6	0
101	Comparison between Clinical and Pathological Staging in Low Stage Nonseminomatous Germ Cell Testicular Tumors. <i>Journal of Urology</i> , 1992, 148, 76-79.	0.2	37
102	Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results. <i>Annals of Oncology</i> , 1992, 3, 211-216.	0.6	24
103	Relation of in vitro Drug Activity to Clinical Response in a Prospective Trial for Advanced Germ Cell Testicular Tumors. <i>European Urology</i> , 1989, 16, 450-455.	0.9	6
104	Difficulties of a Surveillance Study Omitting Retroperitoneal Lymphadenectomy in Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis. <i>Journal of Urology</i> , 1987, 138, 1393-1395.	0.2	75
105	Adjuvant Medroxyprogesterone Acetate and Steroid Hormone Receptors in Category M0 Renal Cell Carcinoma. An Interim Report of a Prospective Randomized Study. <i>Journal of Urology</i> , 1986, 135, 18-21.	0.2	22
106	Successful treatment of good-risk disseminated testicular cancer with cisplatin, bleomycin, and reduced-dose vinblastine. <i>Cancer</i> , 1986, 57, 2114-2118.	2.0	12
107	Cisplatin combination chemotherapy in advanced seminoma. <i>Cancer</i> , 1986, 58, 1625-1629.	2.0	42
108	Unilateral Lymphadenectomy in Intraoperative Stage I Nonseminomatous Germinal Testis Cancer. <i>Journal of Urology</i> , 1985, 134, 485-488.	0.2	106

#	ARTICLE	IF	CITATIONS
109	Surveillance or Lymph Node Dissection in Clinical Stage I Non-seminomatous Germinal Testis Cancer?. British Journal of Urology, 1985, 57, 759-762.	0.1	29
110	Early resection of residual tumor during cisplatin, vinblastine, bleomycin combination chemotherapy in stage III and bulky stage II nonseminomatous testicular cancer. Cancer, 1985, 56, 249-255.	2.0	56
111	Cisplatin and etoposide salvage therapy and resection of the residual tumor in pretreated germ cell testicular cancer. Cancer, 1985, 56, 2399-2403.	2.0	24
112	Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer. Cancer, 1985, 56, 2411-2415.	2.0	76
113	Retroperitoneal lymphadenectomy and aggressive chemotherapy in nonbulky clinical stage II nonseminomatous germinal testis tumors. Cancer, 1984, 53, 1363-1368.	2.0	21
114	Steroid hormone receptors in normal and malignant human renal tissue: Relationship with progestin therapy. The Journal of Steroid Biochemistry, 1984, 21, 329-335.	1.3	40
115	Hormone Treatment and Sex Steroid Receptors in Metastatic Renal Cell Carcinoma: Report of a Multicentric Prospective Study. Tumori, 1983, 69, 215-220.	0.6	16